drugset / Trial / NCT02207556

Doxycycline to Upgrade Organ Response in Light Chain (AL) Amyloidosis Trial

NCT02207556

NaSingle-groupOpen-labelTreatment

Summary

In this study the investigators want to find out more about the addition of the antibiotic, doxycycline, to standard anti-amyloid therapy in people with amyloidosis. The investigators want to find out whether doxycycline improves the response to standard anti-amyloid therapy and whether it causes any problems (side effects).

Timeline

Start
2014-10-01
Primary completion
2017-07-31
Completion
2020-05-19

Drugs

EvaluationDrugModalityDoseRoute
Subject Doxycycline Small molecule 100 mg Oral